基本信息
浏览量:165
职业迁徙
个人简介
Novel Molecular Therapeutics in Bladder Cancer
Meng is interested in developing novel therapeutic interventions for bladder cancer and initiating clinical trials using these agents. Elizabeth Blackburn, PhD has discovered that targeting the telomerase within cancer cells is able to effectively kill the cancer cells. In collaboration Meng and Blackburn are investigating methods of delivering novel agents into the bladder to treat bladder cancer. Current studies are examining this approach in animal models as well as human tumor specimens.
Molecular Predictors of Prostate Cancer
Although many clinical methods of assessing prostate cancer exist, few molecular markers for disease behavior have been identified. Meng investigated the role of MCM2, a novel protein involved in DNA replication in the prostate. He discovered that MCM2 is overexpressed in prostate cancers but not within normal or hyperplastic tissue. Moreover, the level of MCM2 in the specimen after prostatectomy was able to accurately predict how patients fared after surgery. MCM2, as well as other molecular markers, are important in determining the prognosis in patients with prostate cancer and may help lead to discovery of crucial steps in prostate cancer development.
Minimally Invasive Approaches to Urologic Cancer
The revolution in minimally invasive surgery (laparosopy) has expanded to include all areas of urology, including oncology. Meng has had a long-standing interest in the application of laparoscopy for treating cancers of the urologic system. During his fellowship he performed laparoscopic surgery for cancers of the kidney, ureter, bladder, adrenal gland, and prostate. Meng helped develop and perform novel minimally invasive operations, publishing over 13 manuscripts on the topic. His main area of laparoscopic interest is the pathologic examination of specimens for cancer after laparoscopy and studying the outcomes in these patients.
He then attended the Johns Hopkins School of Medicine where he was inducted into the Alpha Omega Alpha honor society. Meng obtained his general surgery and urology training at the University of California San Francisco. Subsequently, he combined his interest in urologic oncology and minimally invasive surgery, completing fellowships in both under the guidance of Peter Carroll, MD, MPH and Marshall Stoller, MD. Upon completion of his fellowships Meng has continued as UCSF faculty specializing in urologic cancers and laparoscopy. He is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center located at the Mission Bay Medical Center. He also operates at San Francisco General Hospital. Meng teaches laparoscopic techniques at the UCSF Urologic Laparoscopy course, and he has moderated the laparoscopy session at the Western Section of the AUA. Meng has written over 50 peer-reviewed publications and 9 chapters covering many aspects of oncology, minimally invasive surgery, and renal trauma. And, in 2013, he was named Chief of Urologic Oncology.
In 2015 Maxwell Meng, MD was named Assistant Editor of The Journal of Urology, the official journal of the American Urological Association. In his role as one of the fourteen assistant editors, he will help manage review of bladder, kidney and testis cancer submissions.
Click here for an interview with Dr. Meng and Nathan Adrian, the American competitive swimmer and 8-time Olympic medalist on the importance of regular self-testicular exams.
Meng's clinical interests include the diagnosis and management of genitourinary malignancy, and minimally invasive treatment of benign and malignant diseases. He has experience with robotic surgery and is actively involved in the development of new technologies. Meng is an active member of the American Urological Association (AUA), an active member of the Western Section of the AUA, and a candidate member of the American College of Surgeons.
Meng is interested in developing novel therapeutic interventions for bladder cancer and initiating clinical trials using these agents. Elizabeth Blackburn, PhD has discovered that targeting the telomerase within cancer cells is able to effectively kill the cancer cells. In collaboration Meng and Blackburn are investigating methods of delivering novel agents into the bladder to treat bladder cancer. Current studies are examining this approach in animal models as well as human tumor specimens.
Molecular Predictors of Prostate Cancer
Although many clinical methods of assessing prostate cancer exist, few molecular markers for disease behavior have been identified. Meng investigated the role of MCM2, a novel protein involved in DNA replication in the prostate. He discovered that MCM2 is overexpressed in prostate cancers but not within normal or hyperplastic tissue. Moreover, the level of MCM2 in the specimen after prostatectomy was able to accurately predict how patients fared after surgery. MCM2, as well as other molecular markers, are important in determining the prognosis in patients with prostate cancer and may help lead to discovery of crucial steps in prostate cancer development.
Minimally Invasive Approaches to Urologic Cancer
The revolution in minimally invasive surgery (laparosopy) has expanded to include all areas of urology, including oncology. Meng has had a long-standing interest in the application of laparoscopy for treating cancers of the urologic system. During his fellowship he performed laparoscopic surgery for cancers of the kidney, ureter, bladder, adrenal gland, and prostate. Meng helped develop and perform novel minimally invasive operations, publishing over 13 manuscripts on the topic. His main area of laparoscopic interest is the pathologic examination of specimens for cancer after laparoscopy and studying the outcomes in these patients.
He then attended the Johns Hopkins School of Medicine where he was inducted into the Alpha Omega Alpha honor society. Meng obtained his general surgery and urology training at the University of California San Francisco. Subsequently, he combined his interest in urologic oncology and minimally invasive surgery, completing fellowships in both under the guidance of Peter Carroll, MD, MPH and Marshall Stoller, MD. Upon completion of his fellowships Meng has continued as UCSF faculty specializing in urologic cancers and laparoscopy. He is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center located at the Mission Bay Medical Center. He also operates at San Francisco General Hospital. Meng teaches laparoscopic techniques at the UCSF Urologic Laparoscopy course, and he has moderated the laparoscopy session at the Western Section of the AUA. Meng has written over 50 peer-reviewed publications and 9 chapters covering many aspects of oncology, minimally invasive surgery, and renal trauma. And, in 2013, he was named Chief of Urologic Oncology.
In 2015 Maxwell Meng, MD was named Assistant Editor of The Journal of Urology, the official journal of the American Urological Association. In his role as one of the fourteen assistant editors, he will help manage review of bladder, kidney and testis cancer submissions.
Click here for an interview with Dr. Meng and Nathan Adrian, the American competitive swimmer and 8-time Olympic medalist on the importance of regular self-testicular exams.
Meng's clinical interests include the diagnosis and management of genitourinary malignancy, and minimally invasive treatment of benign and malignant diseases. He has experience with robotic surgery and is actively involved in the development of new technologies. Meng is an active member of the American Urological Association (AUA), an active member of the Western Section of the AUA, and a candidate member of the American College of Surgeons.
研究兴趣
论文共 283 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Heiko Yang,Hanbing Song,Paul Allegakoen,Kevin Lu, Elizabeth Yip, Keliana Hui,Kevin Chang, Corynn Kasap, Janae Gayle,Bradley A. Stohr,Maxwell V. Meng,Arun Wiita,
Prostate Cancer and Prostatic Diseasesno. 4 (2023): 759-764
JOURNAL OF UROLOGY (2023): E245-E245
引用0浏览0引用
0
0
Urologic oncologyno. 8 (2023): 355.e19-355.e28
Clinical genitourinary cancerno. 5 (2023): e394-e404
引用0浏览0WOS引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn